Dendrite International, Inc. Announces First Quarter Conference Call.

Business Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--April 12, 2001

Dendrite International, Inc., the leading provider of sales productivity solutions, analytics, data and sales support services for the worldwide pharmaceutical industry (NASDAQ/NMS: DRTE), announced today that it will release its first quarter earnings after the close of the NASDAQ market on Wednesday, April 18th, 2001. A conference call will take place at 4:30 P.M., Eastern Standard Time, on that date. In addition to the call, anyone interested may listen by logging onto the Dendrite website at www.Dendrite.com, for a live simulcast. Replay information will be available through the company's website following the completed earnings call.

ABOUT DENDRITE

Dendrite International, Inc. (NASDAQ/NMS:DRTE) designs and supports technology-based knowledge systems that enhance the competitive activities of the sales forces of the world's largest pharmaceutical companies. Approximately one-third of all pharmaceutical sales representatives and their managers worldwide rely on Dendrite. www.dendrite.com

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The aforementioned conference call may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements are made a number of times and may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," "target" and similar statements or variations of such terms. Such forward-looking statements are based on our current expectations, assumptions, estimates and projections about the Company and involve certain significant risks and uncertainties, including: (i) dependence on the pharmaceutical industry; (ii) fluctuations in quarterly results of operations; (iii) unpredictability of quarterly revenues due to lengthy selling cycles; (iv) fluctuations in quarterly operating results due to fixed costs if revenues fall below expectations; (v) variations in customer budget cycles; (vi) loss of any one or more major customers; (vii) unsuccessful introduction of new products or unsuccessful response to technological changes; (viii) timing of revenue recognition being dependent on many factors, many of which are outside the Company's control; (ix) increased competition may result in price reductions and decreased demand for the Company's products and services; (x) customers' reliance on competitors for market data; (xi) dependence on retention of key senior management team; (xii) our ability to manage future growth efficiently; (xiii) our ability to successfully develop, market, and maintain as proprietary, all technology used in or marketed as part of our business; and (xiv) the consumer packaged goods industry may have unfamiliar characteristics from those of the pharmaceutical industry. As a result of these and other important factors that may be contained in the Company's annual reports on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission, actual results may differ materially from such forward-looking statements. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation that such forward-looking statements will be achieved. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statement.